Vertex Pharmaceuticals (Nasdaq:VRTX) announced today that the FDA lifted the clinical hold placed on the Phase 1/2 trial of VX-880. Boston-based Vertex designed VX-880 as a stem cell-derived fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. It could potentially restore the body’s ability […]
Pharmaceuticals
Teva appoints former Vertex exec as new head of R&D, CMO
Teva Pharmaceuticals (NYSE:TEVA) announced today that it appointed Dr. Eric A. Hughes as VP of global R&D and chief medical officer. Hughes’ employment becomes effective Aug. 1, 2022, and he will be based out of Tel Aviv, Israel-based Teva’s U.S. headquarters in Parsippany, New Jersey. The company develops generic and specialty medicines, including inhalation solutions. […]
West Pharmaceutical Services debuts new needle syringe system
West Pharmaceutical Services (NYSE:WST) announced the recent unveiling of its Daikyo Crystal Zenith needle syringe system. Exton, Pennsylvania–based West designed the Daikyo Crystal Zenith 2.25mL insert needle syringe system as a technologically advanced cyclic olefin polymer containment and delivery system. It’s meant to offer an alternative to glass, mitigating the risk of breakage and reducing […]
ReCode raises $200M series B for next-gen lipid nanoparticle delivery platform
ReCode Therapeutics announced today that it closed a Series B extension financing round, adding $120 million in new funds. Menlo Park, California-based ReCode, which develops the selective organ targeting (SORT) lipid nanoparticle technology (LNP) delivery platform, has now raised $200 million total in the Series B. New investors Leaps by Bayer (the impact investment unit […]
Advanced NanoTherapies closes $7.2M Series A for drug-coated balloon
Advanced NanoTherapies announced today that it closed an oversubscribed Series A equity financing round. Los Gatos, California-based Advanced NanoTherapies, which develops the SirPlux Duo drug-coated balloon (DCB) for treating de novo coronary artery disease (CAD) lesions, has now raised $12.5 million in total since September 2020. The company said in a news release that the […]
Virpax to pursue over-the-counter pathway for topical spray treatment for osteoarthritis pain
Virpax Pharmaceuticals (Nasdaq:VRPX) announced today that it will pursue a direct to over-the-counter (OTC) regular pathway for Epoladerm. Berwyn, Pennsylvania–based Virpax designed the Epoladerm investigational pre-filled topical spray analgesic product for the non-addictive management of chronic pain associated with osteoarthritis (OA) of the knee. According to a news release, the company expects the direct to […]
Inovio names new chief medical officer
Inovio (Nasdaq:INO) announced today that it appointed Dr. Michael Sumner as its new chief medical officer (CMO). Sumner will oversee Inovio’s clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, along with regulatory affairs, pharmacovigilance and medical affairs. He will also serve on the company’s executive leadership team and report to […]
Vivera adds two industry veterans to its technology advisory board
Vivera announced today that it added Robert Massoudi and Bryan Hughes to its technology advisory board. Massoudi and Hughes will support Newport Beach, California–based Vivera in its product and software development initiatives while forging strategic partnerships for Zicoh, the company’s electronic dose-controlled medication delivery system designed to improve prescription drug adherence, including medications with a […]
FDA grants breakthrough nod for Carthera’s SonoCloud-9
Carthera announced today that it received FDA breakthrough device designation for its SonoCloud-9 system. Paris-based Carthera designed SonoCloud-9 for implantation in a skull window below the skin. Once in place, the device becomes invisible. When activated for a few minutes using a transdermal needle connected to an external control unit, it uses low-intensity pulsed ultrasound to […]
InfuSystem, Ventis Pharma enter pain management marketing deal
InfuSystem (NSYE:INFU) announced today that it entered into a national sales and marketing agreement with Ventis Pharma. Rochester Hills, Michigan-based InfuSystem’s partnership with Ventis will focus on sales and marketing for the latter’s patented Endura-Kit brand of Enduracaine, a local anesthetic compound. The kit consists of three non-opioid drugs: tetracaine, lidocaine and epinephrine. Ventis Pharma […]
